Loading...
Although several biologic agents have received FDA approval for treating psoriasis in adults, none have been evaluated for pediatric patients. To evaluate the safety and efficacy of the TNF inhibitor etanercept in children and adolescents with moderate-to-severe psoriasis, investigators performed a 42-site, double-blind, placebo-controlled trial in 211 patients (age range, 4–17 years; mean PASI score, 16.4). Half the patients received a weekly subcutaneous injection of etanercept (0.8 mg/kg to a maximum of 50 mg/week), and the other half received a placebo injection. After 12 weeks of treatment, 57% of the etanercept group but only 11% of the placebo group had improved by at least 75% (PASI, 75). All but six etanercept recipients continued …